SMS Lifesciences India Limited (SMSLIFE.NS)
INR 1357.1
(3.57%)
INR 1357.1
(3.57%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.9 Billion INR | 15.75% |
| 2022 | 3.37 Billion INR | -5.43% |
| 2021 | 3.56 Billion INR | 18.01% |
| 2020 | 3.02 Billion INR | 19.57% |
| 2019 | 2.52 Billion INR | -6.34% |
| 2018 | 2.69 Billion INR | 52.81% |
| 2017 | 1.76 Billion INR | -0.09% |
| 2016 | 1.76 Billion INR | 2.6% |
| 2015 | 1.72 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 3.9 Billion INR | 15.75% |
| 2023 Q4 | 3.9 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 3.33 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.75 Billion INR | 0.0% |
| 2022 FY | 3.37 Billion INR | -5.43% |
| 2022 Q4 | 3.37 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q2 | 3.42 Billion INR | 0.0% |
| 2021 Q4 | 3.56 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 3.56 Billion INR | 18.01% |
| 2020 Q2 | 2.7 Billion INR | 0.0% |
| 2020 FY | 3.02 Billion INR | 19.57% |
| 2020 Q4 | 3.02 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 2.55 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 2.52 Billion INR | -6.34% |
| 2019 Q4 | 2.52 Billion INR | 0.0% |
| 2018 FY | 2.69 Billion INR | 52.81% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 2.69 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 2.33 Billion INR | 0.0% |
| 2017 FY | 1.76 Billion INR | -0.09% |
| 2017 Q2 | 1.82 Billion INR | 0.0% |
| 2017 Q4 | 1.76 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 1.76 Billion INR | 2.6% |
| 2016 Q4 | 1.76 Billion INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2015 FY | 1.72 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Biocon Limited | 560.7 Billion INR | 99.304% |
| Blue Jet Healthcare Limited | 10.58 Billion INR | 63.118% |
| Concord Biotech Limited | 17 Billion INR | 77.038% |
| Dishman Carbogen Amcis Limited | 95.81 Billion INR | 95.924% |
| Jubilant Ingrevia Limited | 47.31 Billion INR | 91.747% |
| Lyka Labs Limited | 1.56 Billion INR | -149.176% |
| Panacea Biotec Limited | 12.4 Billion INR | 68.524% |
| Piramal Pharma Limited | 153.11 Billion INR | 97.45% |
| Supriya Lifescience Limited | 9.21 Billion INR | 57.609% |
| Syngene International Limited | 61.51 Billion INR | 93.652% |
| TAKE Solutions Limited | 881.05 Million INR | -343.243% |
| Zota Health Care Limited | 2.28 Billion INR | -71.034% |